In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states

Diagnostic Microbiology and Infectious Disease

Volumn 85, Issue 3, 2016, Pages 356-359

  Velez Perez, Antonio L ^a,b   Schmidt Malan, Suzannah M ^a   Kohner, Peggy C ^a   Karau, Melissa J ^a   Greenwood Quaintance, Kerryl E ^a   Patel, Robin ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Biofilm; Ceftolozane; Pseudomonas aeruginosa; Tazobactam

Indexed keywords

CEFEPIME; CEFTOLOZANE; TAZOBACTAM; BETA LACTAMASE INHIBITOR; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; URINARY TRACT ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BIOFILM; CONTROLLED STUDY; IN VITRO STUDY; MIC50; MIC90; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM BIOFILM BACTERICIDAL CONCENTRATION; MINIMUM BIOFILM INHIBITORY CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANKTON; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY; PSEUDOMONAS INFECTION;

ANTI-INFECTIVE AGENTS, URINARY; BETA-LACTAMASE INHIBITORS; BIOFILMS; CEPHALOSPORINS; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84964597352     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2016.02.014     Document Type: Article

References (14)

1. Ceri, H., Olson, M., Stremick, C., Read, R., Morck, D., Buret, A., The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37 (1999), 1771–1776.
2. Clinical and Laboratory Standards Institute (CLSI), Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—tenth edition. CLSI document M07-A10, 2015, CLSI, Wayne, PA.
3. Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement M100-S25. 2015, CLSI, Wayne, PA.
4. Farrell, D.J., Flamm, R.K., Sader, H.S., Jones, R.N., Antimicrobial activity of ceftolozane/tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in US hospitals (2011-2012). Antimicrob Agents Chemother 57:12 (2013), 6305–6310 [AAC.01802-01813].
5. Frank, K.L., Reichert, E.J., Piper, K.E., Patel, R., In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates. Antimicrob Agents Chemother 51 (2007), 888–895.
6. Hill, D., Rose, B., Pajkos, A., Robinson, M., Bye, P., Bell, S., et al. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol 43 (2005), 5085–5090.
7. Kuti, J.L., Pettit, R.S., Neu, N., Cies, J.J., Lapin, C., Muhlebach, M.S., et al. Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis. Diagn Microbiol Infect Dis 83:1 (2015), 53–55.
8. Polovina, M., Potpara, T., Milosevic, I., Stepanovic, J., Jovanovic, M., Pavlovic, M., Mitral valve endocarditis caused by Pseudomonas aeruginosa: a case report. J Infect Dev Ctries 8 (2014), 676–679.
9. Rodríguez‐Pardo, D., Pigrau, C., Lora‐Tamayo, J., Soriano, A., Toro, M., Cobo, J., et al. Gram‐negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. Clin Microbiol Infect 20 (2014), O911–O919.
10. Sader, H.S., Farrell, D.J., Castanheira, M., Flamm, R.K., Jones, R.N., Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12). J Antimicrob Chemother 69:10 (2014), 2713–2722 [dku184].
11. Shlaes, D.M., New β‐lactam–β‐lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci 1277 (2013), 105–114.
12. Skalweit, M.J., Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections. Drug Des Devel Ther 9 (2015), 2919–2925.
13. Soliman, R., Lynch, S., Meader, E., Pike, R., Turton, J.F., Hill, R.L., et al. Successful ceftolozane/tazobactam treatment of chronic pulmonary infection with pan‐resistant Pseudomonas aeruginosa. JMM Case Reports 2 (2015), 1–4 [e000025].
14. Zhanel, G.G., Chung, P., Adam, H., Zelenitsky, S., Denisuik, A., Schweizer, F., et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs 74 (2014), 31–51.